Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Sponsor: Dana-Farber Cancer Institute
This observational or N/A phase trial investigates BK Virus Infection and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2024 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2024 — Jun 2024 [monthly]
Active Not Recruiting
-
May 2023 — Feb 2024 [monthly]
Active Not Recruiting
▶ Show 8 earlier versions
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting
-
Mar 2022 — Feb 2023 [monthly]
Active Not Recruiting
-
Oct 2021 — Mar 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting
-
Dec 2019 — Aug 2020 [monthly]
Recruiting
-
Sep 2018 — Dec 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .